Payment overview · 2025
General Payments
$1,512.72
72 reported records · 22 companies
Healthcare provider profile · identity verified
William Prenatt, MD
Allopathic & Osteopathic Physicians|Family Medicine · MYRTLE BEACH, SC · NPI 1316906191
Verified facts
What the public records show
CMS Open Payments records show William Prenatt, MD received $1,512.72 in general payments during 2025 across 72 reported records.
UCB, Inc. accounted for 17.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Synthroid, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $269.25 | 17.8% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $175.48 | 11.6% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $162.47 | 10.7% | 6 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $148.82 | 9.8% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $134.62 | 8.9% | 11 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $92.96 | 6.2% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $90.88 | 6.0% | 5 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $44.28 | 2.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.14 | 2.9% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $42.52 | 2.8% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $34.57 | 2.3% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $34.52 | 2.3% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $31.28 | 2.1% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $30.00 | 2.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.47 | 1.9% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $28.50 | 1.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.74 | 1.8% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.71 | 1.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.41 | 1.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.68 | 1.2% | 1 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $16.78 | 1.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.64 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,512.72 | 72 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $269.25 | 13 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $148.82 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $97.88 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $92.17 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $90.88 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $83.31 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $64.59 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $60.55 | 6 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $44.28 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $42.52 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $39.94 | 3 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $34.57 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $34.52 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $31.28 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $28.50 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.74 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.74 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.74 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $25.26 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $24.71 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $13.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 112 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 146 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 108 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
108 | 31 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
112 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 16 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
121 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
146 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
42 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 765 | 222 |
| Amlodipine Besylate | Amlodipine Besylate | 568 | 169 |
| Pantoprazole Sodium | Pantoprazole Sodium | 526 | 165 |
| Levothyroxine Sodium | Levothyroxine Sodium | 508 | 143 |
| Losartan Potassium | Losartan Potassium | 507 | 146 |
| Lisinopril | Lisinopril | 435 | 126 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 392 | 113 |
| Metoprolol Succinate | Metoprolol Succinate | 345 | 108 |
| Meloxicam | Meloxicam | 320 | 100 |
| Tamsulosin Hcl | Tamsulosin Hcl | 320 | 98 |
| Omeprazole | Omeprazole | 280 | 87 |
| Gabapentin | Gabapentin | 269 | 88 |
| Alprazolam | Alprazolam | 254 | 54 |
| Metformin Hcl Er | Metformin Hcl | 225 | 69 |
| Simvastatin | Simvastatin | 209 | 57 |
| Trazodone Hcl | Trazodone Hcl | 209 | 63 |
| Tramadol Hcl | Tramadol Hcl | 198 | 78 |
| Furosemide | Furosemide | 193 | 67 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 171 | 62 |
| Azelastine Hcl | Azelastine Hcl | 169 | 86 |
| Metformin Hcl | Metformin Hcl | 166 | 46 |
| Eszopiclone | Eszopiclone | 164 | 49 |
| Quetiapine Fumarate | Quetiapine Fumarate | 158 | 42 |
| Ozempic | Semaglutide | 146 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 145 | 46 |
| Allopurinol | Allopurinol | 142 | 42 |
| Glipizide Er | Glipizide | 140 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 138 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 137 | 36 |
| Bupropion Xl | Bupropion Hcl | 134 | 40 |
| Montelukast Sodium | Montelukast Sodium | 127 | 40 |
| Sertraline Hcl | Sertraline Hcl | 126 | 32 |
| Januvia | Sitagliptin Phosphate | 124 | 35 |
| Mounjaro | Tirzepatide | 121 | 26 |
| Clonazepam | Clonazepam | 116 | 26 |
| Chlorthalidone | Chlorthalidone | 113 | 38 |
| Farxiga | Dapagliflozin Propanediol | 112 | 33 |
| Temazepam | Temazepam | 112 | 48 |
| Diclofenac Sodium | Diclofenac Sodium | 110 | 35 |
| Famotidine | Famotidine | 110 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 36 |
| Synthroid | Levothyroxine Sodium | 108 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 106 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 18 |
| Carvedilol | Carvedilol | 105 | 32 |
| Prednisone | Prednisone | 104 | 87 |
| Azithromycin | Azithromycin | 101 | 93 |
| Eliquis | Apixaban | 101 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 29 |
| Lorazepam | Lorazepam | 89 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 84 | 13 |
| Diazepam | Diazepam | 82 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 81 | 52 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 79 | 59 |
| Pregabalin | Pregabalin | 76 | 15 |
| Finasteride | Finasteride | 73 | 23 |
| Ibuprofen | Ibuprofen | 72 | 18 |
| Celecoxib | Celecoxib | 71 | 28 |
| Valsartan | Valsartan | 71 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 18 |
| Jardiance | Empagliflozin | 68 | 16 |
| Ezetimibe | Ezetimibe | 67 | 19 |
| Potassium Chloride | Potassium Chloride | 67 | 22 |
| Atenolol | Atenolol | 66 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 66 | 19 |
| Glimepiride | Glimepiride | 65 | 16 |
| Mirtazapine | Mirtazapine | 65 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 64 | 18 |
| Benazepril Hcl | Benazepril Hcl | 62 | 17 |
| Memantine Hcl | Memantine Hcl | 61 | 20 |
| Buspirone Hcl | Buspirone Hcl | 60 | 16 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 60 | 20 |
| Donepezil Hcl | Donepezil Hcl | 60 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 38 |
| Glipizide | Glipizide | 56 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 14 |
| Valacyclovir | Valacyclovir Hcl | 53 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 14 |
| Ketoconazole | Ketoconazole | 49 | 33 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 13 |
| Amoxicillin | Amoxicillin | 45 | 41 |
| Spironolactone | Spironolactone | 45 | 16 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 43 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 42 | 42 |
| Alendronate Sodium | Alendronate Sodium | 41 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Ramipril | Ramipril | 41 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 12 |
| Warfarin Sodium | Warfarin Sodium | 40 | 12 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 38 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Fenofibrate | Fenofibrate | 36 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 11 |
| Mupirocin | Mupirocin | 35 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 32 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Estradiol | Estradiol | 27 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Febuxostat | Febuxostat | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | 12 |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 16 |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 11 |
| Methylphenidate Er | Methylphenidate Hcl | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 13 |
| Primidone | Primidone | 16 | suppressed |
| Alprazolam Er | Alprazolam | 15 | suppressed |
| Armodafinil | Armodafinil | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,512.72 · 72 records | UCB, Inc. | ABRYSVO, ACTHAR, AIRSUPRA, Bimzelx, COMIRNATY, EVENITY, FARXIGA, GVOKE HYPOPEN, IBSRELA, INJECTAFER, ISTURISA, JARDIANCE, KRYSTEXXA, LEQVIO, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, QUTENZA, REPATHA, REZDIFFRA, Rybelsus, SYNTHROID, TEPEZZA, TREMFYA, TZIELD, Tymlos, UBRELVY, VRAYLAR, WaveWriter Alpha Prime 16, Wegovy | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error